Medicenna Announces #Trading on the #OTCQX Best Market in the #United States

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that the Company has received approval to commence trading on the OTCQX Best Market, under the symbol, “MDNAF”. The Company’s shares continue to trade on the Toronto Stock Exchange (“TSX”) under the symbol “MDNA”.

OTCQX is an established market for global and growth companies with high financial standards. Investors can find current financial disclosure and Real-Time Level 2 quotes for Medicenna at

“We are very pleased to be trading on the OTCQX as it will improve the Company’s ability to attract a wider audience of investors from both inside and outside the United States. This corporate milestone will provide additional visibility within the investment community enabling us to build awareness more broadly and expand our current shareholder base in order to drive shareholder value”, said Elizabeth Williams, Chief Financial Officer of Medicenna.

“Medicenna Therapeutics joins an impressive roster of Canadian companies, including more than 25 added this year, that cross-trade their shares on the OTCQX market to maximize their reach to U.S. investors. Trading on OTCQX will enable Medicenna to efficiently broaden accessibility to their news and financial disclosure and build visibility among U.S. investors,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group.

Medicenna Therapeutics was sponsored for OTCQX by Burns Figa & Will PC, a qualified third-party firm responsible for providing guidance on OTCQX requirements and recommending membership.

About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs). Its wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna’s lead IL4-EC, MDNA55 is enrolling patients in a CPRIT (Cancer Prevention and Research Institute of Texas) funded Phase 2b clinical trial for recurrent glioblastoma (rGBM) at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna’s IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, OTC Markets connects a diverse network of broker-dealers that provide liquidity and execution services. The company enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

Leave a Reply

Your email address will not be published. Required fields are marked *